Target intelligence / Profile preview

Potassium channel tetramerization domain-containing protein 2 (KCTD2)

Target
KCTD2
Molecular classification
Other (adapter protein), Ubiquitin ligase adaptor, BTB domain-containing protein
01

Overview

Potassium channel tetramerization domain-containing protein 2 (KCTD2) is a soluble, non-channel protein that functions primarily as an adaptor for Cullin3-dependent E3 ubiquitin ligase complexes, facilitating the ubiquitination and degradation of specific substrates including the oncogene c-Myc. The protein has a conserved BTB/POZ domain that mediates oligomerization and protein interactions. KCTD2 is implicated in transcriptional repression, cytoskeleton regulation, and modulation of stem cell features in tumors. It is evolutionarily related to the tetramerization domains of voltage-gated potassium channels, despite not forming a channel itself. Its role in the ubiquitination pathway has been highlighted in cancers, especially malignant gliomas, where its loss leads to increased c-Myc levels, promoting tumor growth and stemness[1][2][5].

Other names
BTB/POZ domain-containing protein KCTD2KCTD2KIAA0176Potassium channel tetramerization domain-containing protein 2potassium channel tetramerisation domain containing 2
02

Mechanism of action

Adaptor-mediated ubiquitination and degradation of target proteins such as c-Myc (a key stem cell factor and oncogene); Suppression of stem cell-like features and aerobic glycolysis in glioma cells via c-Myc regulation

03

Biological functions

Protein ubiquitination (adaptor for Cullin3 E3 ubiquitin ligase)Transcriptional repressionCytoskeleton regulationTetramerization and gating of ion channels
04

Disease associations

Cancer (notably glioma and glioma stem cell regulation)Other (possible involvement in other diseases related to protein degradation and cellular signaling)
05

Safety considerations

There are currently no documented therapeutic safety concerns specific to KCTD2 targeting, but targeting ubiquitin pathways often carries risks such as off-target protein degradation and dysregulation of cellular homeostasis
06

Biomarkers

KCTD2 expression levels (for tumor characterization, especially in glioma stem cells)c-Myc degradation status (as a downstream effect of KCTD2 activity)

Beyond the preview

Go deeper on Potassium channel tetramerization domain-containing protein 2 (KCTD2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Potassium channel tetramerization domain-containing protein 2 (KCTD2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call